The summed CD8+ T cell ICS response after rAd5 vector boost ranged from 0.02 to 2.32% of total CD8+ T cells, with a median of 0.25%.
By combining the highest response to an Env with the responses to Gag, Pol, and Nef the total ELISpot response after rAd5 vector boost ranged from 195 to 4548 SFC/million PBMCs with a median of 891.
Hy-IoT provides prolonging for the network life time ranging from 47.8% to 92.5% based on the heterogeneity level and also the average throughput was boosted ranging from 11.5% to 70.1% based on the heterogeneity level.
Estimates of boosting ranged from 32% 41% of skin test converters with increasing age.
Using this figure, the proportion of tuberculin test conversion due to boosting can be estimated from the predicted probability of being ELISPOT negative at both recruitment and follow-up: allowing for a specificity adjustment (assuming 80% specificity of the ELISPOT), the proportion of skin test converters estimated to have boosting ranged from 32% to 41% with increasing age.
The magnitude of peak CD4+ T cell ICS response to EnvA after rAd5 vector boosting ranged from 0 to 0.45 percent of total CD4+ T cells and was stable and persisted at a constant level for the remainder of the 6 month follow-up period.
Combining the responses to the distinct gene-specific peptide pools, the summed (best Env + Gag + Pol + Nef) CD4+ T cell ICS response after rAd5 vector boosting ranged from 0.065 to 0.69% of total CD4+ T cells, with a median of 0.22%.
The Gag-specific response after rAd5 boosting ranged from 0 to 0.57% of total CD8+ T cells and was significantly higher than after DNA alone (p = .004), and it trended higher than after rAd5 only, but did not reach statistical significance (p = .291).291
A total of 123 patients with localized germinomas from the Japanese Germ Cell Tumor Study Group (JGCTSG) were treated with induction chemotherapy plus whole ventricular (range, 20 24 Gy) and local boost (range, 30 36 Gy) irradiation.
Seven of these models include exogenous boosting (defined as an exponential decay) with a peak value of 1.3, a boosting duration ranging between 2 and 15 years, no endogenous boosting, a weekly VZV reactivation probability and an annual VZV-CMI loss (= waning) estimated to be 1 1.5% and 1 2%, respectively.
